Overview

XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Status:
Unknown status

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials

Collaborator:

Hoffmann-La Roche

Treatments:

Bevacizumab
Capecitabine